Cheng-Hsien Lin1, Yi-Jiun Su2, Chiann-Yi Hsu3, Po-Nan Wang2, Chieh-Lin Jerry Teng1,4,5. 1. Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. 2. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan. 3. Biostatistics Task Force, Taichung Veterans General Hospital, Taichung, Taiwan. 4. Department of Life Science, Tunghai University, Taichung, Taiwan. 5. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Abstract
BACKGROUND: Owing to the shortage of hematopoietic stem cells from matched sibling donors (MSD) and matched unrelated donors (MUD), the number of patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) has rapidly increased. Despite a comparable overall survival (OS) and leukemia-free survival using this approach, some evidence suggests that haploidentical allo-HSCT recipients have a higher incidence of cytomegalovirus (CMV) infection, though this has not been clearly established. METHODS: This study retrospectively compared the cumulative incidence of CMV DNAemia, 2-year OS, and leukemia-free survival rates in acute leukemia patients with MSD (n = 41), MUD (n = 18), and haploidentical donor allografts (n = 21). RESULTS: The cumulative incidences of CMV DNAemia at day 180 in the MSD, MUD, and haploidentical groups were 39.0, 55.6, and 85.7%, respectively (P < 0.000). As less than 50% of patients in the MSD group were detected to have CMV DNAemia, the median time to CMV DNAemia detection in patients allografted with MSD could not be obtained. However, it was 42 and 29 days, respectively, for the MUD and haploidentical groups. Multivariate analysis revealed that haploidentical allo-HSCT (MSD vs. haploidentical: HR: 0.26; 95% CI: 0.09-0.78; P = 0.017) and age (HR: 1.03; 95% CI: 1.01-1.06; P = 0.011) increased CMV infection. Finally, MSD, MUD, and haploidentical allo-HSCT provided comparable 2-year OS rates (52.1%, 65.5%, and 65.6%; P = 0.425) and 2-year leukemia-free survival rates (67.1%, 68.3%, and 80.7%, P = 0.837). CONCLUSION: The CMV incidence was higher for haploidentical allo-HSCT than for MSD and MUD allo-HSCT; this could be explained by graft-versus-host disease prophylaxis by multiple immunosuppressants.
BACKGROUND: Owing to the shortage of hematopoietic stem cells from matched sibling donors (MSD) and matched unrelated donors (MUD), the number of patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) has rapidly increased. Despite a comparable overall survival (OS) and leukemia-free survival using this approach, some evidence suggests that haploidentical allo-HSCT recipients have a higher incidence of cytomegalovirus (CMV) infection, though this has not been clearly established. METHODS: This study retrospectively compared the cumulative incidence of CMV DNAemia, 2-year OS, and leukemia-free survival rates in acute leukemiapatients with MSD (n = 41), MUD (n = 18), and haploidentical donor allografts (n = 21). RESULTS: The cumulative incidences of CMV DNAemia at day 180 in the MSD, MUD, and haploidentical groups were 39.0, 55.6, and 85.7%, respectively (P < 0.000). As less than 50% of patients in the MSD group were detected to have CMV DNAemia, the median time to CMV DNAemia detection in patients allografted with MSD could not be obtained. However, it was 42 and 29 days, respectively, for the MUD and haploidentical groups. Multivariate analysis revealed that haploidentical allo-HSCT (MSD vs. haploidentical: HR: 0.26; 95% CI: 0.09-0.78; P = 0.017) and age (HR: 1.03; 95% CI: 1.01-1.06; P = 0.011) increased CMV infection. Finally, MSD, MUD, and haploidentical allo-HSCT provided comparable 2-year OS rates (52.1%, 65.5%, and 65.6%; P = 0.425) and 2-year leukemia-free survival rates (67.1%, 68.3%, and 80.7%, P = 0.837). CONCLUSION: The CMV incidence was higher for haploidentical allo-HSCT than for MSD and MUD allo-HSCT; this could be explained by graft-versus-host disease prophylaxis by multiple immunosuppressants.
Authors: Dolores Grosso; Benjamin Leiby; Matthew Carabasi; Joanne Filicko-O'Hara; Sameh Gaballa; William O'Hara; John L Wagner; Neal Flomenberg Journal: Front Oncol Date: 2019-09-17 Impact factor: 6.244
Authors: Wei-Ran Lv; Ya Zhou; Jun Xu; Zhi-Ping Fan; Fen Huang; Na Xu; Li Xuan; Peng-Cheng Shi; Hui Liu; Zhi-Xiang Wang; Jing Sun; Qi-Fa Liu Journal: Cancer Med Date: 2021-10-20 Impact factor: 4.452
Authors: Mahasweta Gooptu; Rizwan Romee; Andrew St Martin; Mukta Arora; Monzr Al Malki; Joseph H Antin; Christopher N Bredeson; Claudio G Brunstein; Saurabh Chhabra; Ephraim J Fuchs; Nilanjan Ghosh; Michael R Grunwald; Christopher G Kanakry; Natasha Kekre; Jospeh P McGuirk; Ian K McNiece; Rohtesh S Mehta; Marco Mielcarek; Fillipo Milano; Dipenkumar Modi; Ran Reshef; Scott R Solomon; Mark A Schroeder; Edmund K Waller; Yoshiro Inamoto; Robert J Soiffer; Mary Eapen Journal: Blood Date: 2021-07-22 Impact factor: 25.476